Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

NCT06090786 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

225

Enrollment

OTHER

Sponsor class

Conditions

AML, Adult
Minimal Residual Disease

Interventions

DIAGNOSTIC_TEST: MRD assessment

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto